Menu
Annual · values202520242023202220212020201920182017
Operating Cash Flow-15.57 M USD-16.84 M USD-18.86 M USD-15.62 M USD-11.85 M USD-7.68 M USD-5.90 M USD-6.36 M USD-4.20 M USD
Depreciation & Amortization136000 USD189000 USD220000 USD212000 USD149002 USD97549 USD123660 USD133419 USD139213 USD
Stock-Based Compensation3.42 M USD4.14 M USD5.20 M USD8.99 M USD6.00 M USD693109 USD941962 USD1.92 M USD878404 USD
Capital Expenditures5000 USD37000 USD33000 USD115000 USD367890 USD180291 USD363891 USD12422 USD10938 USD
Cash Flow from Investing15.86 M USD1.33 M USD-7.87 M USD-34.55 M USD-367890 USD-180291 USD-363891 USD-12422 USD165312 USD
Cash Flow from Financing1.02 M USD13.64 M USD25.79 M USD57.61 M USD15.07 M USD5.64 M USD9.03 M USD4.06 M USD
Dividends Paid
Stock Buybacks
Free Cash Flow-15.57 M USD-16.88 M USD-18.89 M USD-15.73 M USD-12.21 M USD-7.86 M USD-6.26 M USD-6.37 M USD-4.21 M USD

EnVVeno Medical Corporation is a biomedical company focused on the development and commercialization of innovative medical treatments. Primarily, the corporation is dedicated to addressing unmet medical needs pertaining to vascular diseases, with a notable emphasis on venous conditions. The company's flagship product centers around a specialized prosthetic device aimed at treating chronic venous insufficiency (CVI), a condition prevalent due to valve failure in veins, leading to poor circulation and various complications. EnVVeno Medical's research and development efforts are channeled towards creating effective solutions that improve patient outcomes and enhance quality of life for individuals affected by these vascular issues. Operating within the healthcare and biotechnology sector, EnVVeno Medical is a key contributor to advancements in medical technology, with its innovative approach underscoring its importance in the medical devices market. By prioritizing cardiovascular health, the corporation plays a critical role in the healthcare industry, supporting the broader objective of developing cutting-edge treatments and addressing critical health challenges.